Mostrar el registro sencillo del ítem

dc.contributor.advisorVargas Diaz, Luis Eduardo
dc.contributor.authorHernandez Gonzalez, Maritza
dc.contributor.authorHerrera Gomez, Yury Katherine
dc.date.accessioned2021-10-27T20:55:22Z
dc.date.available2021-10-27T20:55:22Z
dc.date.issued2018-11
dc.identifier.urihttps://repositorio.unicolmayor.edu.co/handle/unicolmayor/3569
dc.description.abstractDesde que el virus sincitial respiratorio humano (VSRh) fue descubierto, no ha sido posible el desarrollo de profilaxis asequibles que permitan el control de la infección y que a su vez disminuyan los efectos sanitarios y el impacto económico generado por el mismo. El desarrollo de la respuesta inmune adaptativa es uno de los campos que se ha venido explorando como alternativa a dicha problemática. Es así que, la identificación de péptidos antigénicos capaces de formar complejos MHC clase II HLA-DR/péptido resulta de gran importancia como base para la búsqueda de una vacuna segura y eficaz. En este trabajo de investigación se evaluó la capacidad de unión de ocho péptidos provenientes de las proteínas F, L, N, M, G y SH del VSRh para formar complejo HLA-DR/péptido con los alelos HLA- DR1 Y HLA-DR4 del complejo mayor de histocompatibilidad clase II. Para ello se empleó el algoritmo PROPRED y un ensayo de unión competitiva en presencia y ausencia de HLA-DM. Los resultados demuestran una correlación del 68% entre los datos teóricos y experimentales en ausencia de HLA-DM. Por otro lado, se observa que N-298 y L-962 son los péptidos de mayor afinidad por los alelos HLA-DR1 y HLA-DR4, indicando que pueden ser inmunógenos capaces de generar una respuesta inmunitaria efectiva contra el VSRh en individuos HLA-DR1 o HLA-DR4. De manera similar, los resultados sugieren que los péptidos SH-50, G1-58 Y L-832 pueden tener un papel similar a HLA-DM en la modulación de la formación del complejo MHC clase II/péptido.spa
dc.description.tableofcontentsRESUMEN12 INTRODUCCIÓN13 1. OBJETIVOS15 1.1 OBJETIVO GENERAL15 1.2 OBJETIVOS ESPECÍFICOS15 2. JUSTIFICACIÓN16 3. ANTECEDENTES18 4. MARCO TEÓRICO23 4.1 Moléculas MHC clase II: Estructura, función y características de la unión HLA/ péptido23 4.2 Virus sincitial respiratorio humano28 4.2.1 Proteínas no estructurales31 4.2.2 Proteína N31 4.2.3 Proteína M32 4.2.4 Proteína F33 4.2.5 Proteína SH (Small Hydrophobic36 4.2.6 Proteína G38 4.2.7 Proteína L40 4.2.8 Proteína P42 4.3 Respuesta inmune frente al Virus Sincitial Respiratorio Humano43 4.4 Manifestaciones clínicas y diagnóstico del VSRh44 4.5 Epidemiologia44 4.6 Tratamiento y protección frente al VSRh46 4.7 Ensayos inmunoenzimáticos (ELISA48 4.8 Algoritmo predictivo RAGHAVA-PROPRED48 5. DISEÑO METODOLÓGICO50 5.1 Moléculas MHC clase II y HLA-DM50 5.2 Péptido control biotinilado: Hemaglutinina (HA) 306-31850 5.3 Péptidos del virus sincitial respiratorio51 5.4 Determinación del porcentaje de unión empleando el algoritmo PROPRED53 7 5.5 Ensayo de unión MHC clase II/ Péptidos54 5.6 Ensayo de Unión MHC clase II/ Péptidos / HLA-DM56 5.7 Determinación del porcentaje de unión relativo MHC clase II/péptido56 6. RESULTADOS57 6.1 Determinación del porcentaje de unión de los péptidos F-137, L-962, N-298, L-832, L-449, M-68, G1-58 a los alelos HLA-DRB1* 0101 y HLA-DRB1*0401 empleando el algoritmo PROPRED57 6.2 Determinación experimental de los porcentajes de unión relativos de péptidos del VSRh a moléculas HLA-DR1 Y HLA-DR4 en presencia y ausencia de HLA-DM59 6.3 Comparación del porcentaje de unión de cada péptido con HLA-DR1 y HLA- DR4 en presencia y ausencia de HLA-DM63 7. DISCUSIÓN67 8. CONCLUSIONES73 RECOMENDACIONES76 REFERENCIAS77 ANEXOS90spa
dc.format.extent95p.spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherUniversidad Colegio Mayor de Cundinamarcaspa
dc.rightsUniversidad Colegio Mayor de Cundinamarca, 2019spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.titleEvaluación de la unión de ocho péptidos del virus Sincitial respiratorio humano a los alelos MHC clase ii: HLA -DR1 Y HLA - DR4.spa
dc.typeTrabajo de grado - Pregradospa
dc.description.degreelevelPregradospa
dc.description.degreenameBacteriólogo(a) y Laboratorista Clínicospa
dc.identifier.barcode58651
dc.publisher.facultyFacultad de Ciencias de la Saludspa
dc.publisher.placeBogotá D.Cspa
dc.publisher.programBacteriología y Laboratorio Clínicospa
dc.relation.referencesSimões, Eric A. F., Louis Bont, Paolo Manzoni, Brigitte Fauroux, Bosco Paes, Josep Figueras-Aloy, Paul A. Checchia, and Xavier Carbonell-Estrany. 2018. “Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.” Infectious Diseases and Therapy 7 (1): 87–120. doi:10.1007/s40121-018-0188-z.spa
dc.relation.referencesSingh, Harpreet, and G. P.S. Raghava. 2002. “ProPred: Prediction of HLA-DR Binding Sites.” Bioinformatics 17 (12): 1236–37. doi:10.1093/bioinformatics/17.12.1236.spa
dc.relation.referencesCollins, Peter L., Rachel Fearns, and Barney S. Graham. 2013. “Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease.” Current Topics in Microbiology and Immunology 372: 3–38. doi:10.1007/978-3-642-38919-1-1.spa
dc.relation.referencesLiang, Bo, Sonja Surman, Emerito Amaro-Carambot, Barbora Kabatova, Natalie Mackow, Matthias Lingemann, Lijuan Yang, et al. 2015. “Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.” Edited by T. S. Dermody. Journal of Virology 89 (18): 9499–9510. doi:10.1128/JVI.01373-15.spa
dc.relation.referencesKim, Joo Young, and Jun Chang. 2016. “In Hot Pursuit of the First Vaccine against Respiratory Syncytial Virus.” Yonsei Medical Journal. Yonsei University College of Medicine. doi:10.3349/ymj.2016.57.4.809.spa
dc.relation.referencesNair, Harish, D. James Nokes, Bradford D. Gessner, Mukesh Dherani, Shabir A. Madhi, Rosalyn J. Singleton, Katherine L. O’Brien, et al. 2010. “Global Burden of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children: A Systematic Review and Meta-Analysis.” The Lancet 375 (9725): 1545–55. doi:10.1016/S0140-6736(10)60206-1spa
dc.relation.referencesWalsh, Edward E. 2011. “Respiratory Syncytial Virus Infection in Adults.” Seminars in Respiratory and Critical Care Medicine 32 (4): 423–32. doi:10.1055/s-0031-1283282.spa
dc.relation.referencesParamore, L. Clark, Vincent Ciuryla, Gabrielle Ciesla, and Larry Liu. 2004. “Economic Impact of Respiratory Syncytial Virus-Related Illness in the US: An Analysis of National Databases.” PharmacoEconomics 22 (5): 275–84. doi:10.2165/00019053-200422050-00001.spa
dc.relation.referencesKarime, L., Arango, O., & Durán, M. A. (2016). Virus sincitial respiratorio (vsr) en menores de 5 años, colombia, 2012 - 2016, 2012–2016. Retrieved from http://www.ins.gov.co/tramites-y-servicios/examenes-de-interés-en-salud-publica/Virologa/VSR en menores de 5 años.pdfspa
dc.relation.referencesInstituto Nacional de Salud. 2017. semana epidemiológica número 50. https://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/2017%20Bolet%C3%ADn%20epidemiol%C3%B3gico%20semana%2051.pdf?fbclid=IwAR0ycbHjXH1fDNI8jg156t0heaVcUf-RN6upV8LQubI1VT0GDFn6L7taXLUspa
dc.relation.referencesInstituto Nacional Salud. 2018. semana epidemiológica número 41. https://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/2018%20Bolet%C3%ADn%20epidemiol%C3%B3gico%20semana%2042.pdf?fbclid=IwAR27t1AfPANtFLqlqWn6caulmGE5n82cCyTGg__dvlqa4suT6W2RKlnuzYMspa
dc.relation.referencesBarbosa, Juliana, Beatriz Parra, Alarcón Liliana, Flor Inés Quiñones, Eduardo López, and Manuel Antonio Franco. 2017. “Prevalencia y Periodicidad Del Virus Sincitial Respiratorio En Colombia.” Rev. Acad. Colomb. Cienc. Ex. Fis. Nat. 41 (161): 435–46. doi:http://dx.doi.org/10.18257/raccefyn.511.spa
dc.relation.referencesTorres, Sandra Mónica Estupiñán, and Esperanza Trujillo Gama. 2004. “Complejo Mayor de Histocompatibilidad y Desarrollo de Vacunas.” NOVA. http://www.unicolmayor.edu.co/publicaciones/index.php/nova/article/view/24/47.spa
dc.relation.referencesSánchez-Trincado, J. L., Gomez-Perosanz, M., & Reche, P. A. (2017). Fundamentals and Methods for T- and B-Cell Epitope Prediction. Journal of Immunology Research. Hindawi Limited. https://doi.org/10.1155/2017/2680160spa
dc.relation.referencesArias-Murillo, Y., Castro-Jiménez, M., Ríos-Espinosa, M., López-Rivera, J., Echeverry-Coral, S., y Martínez-Nieto, O. (2011). Análisis de frecuencias alélicas, genotípicas y haplotípicas de HLA-A, HLA-B, HLA-DRB1 en la población colombiana. Colombia MéDica, 41 (4), 336-343. http://colombiamedica.univalle.edu.co/index.php/comedica/article/view/725/1186.spa
dc.relation.referencesRodríguez Libia M, Giraldo Mabel C, García Natalia, Velásquez Laura, París Sara C, Álvarez Cristiam M et al . Frecuencias alélicas, genotípicas y haplotípicas HLA-A, HLA-B, HLA-DRB1 en donantes fallecidos, Medellín, Colombia. Biomédica [Internet]. 2007 Dec [cited 2018 Oct 27]; 27( 4 ): 537-547. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-41572007000400009&lng=en.spa
dc.relation.referencesPainter, Corrie A, and Lawrence J Stern. 2011. “Structural Insights Into HLA-DM Mediated MHC II Peptide Exchange.” Current Topics in Biochemical Research 13 (2): 39–55. doi:10.1016/j.biotechadv.2011.08.021.Secreted.spa
dc.relation.referencesVargas L.E. et al. (2003) MHC allele-specific binding of a malaria peptide makes it become promiscuous on fitting a glycine residue into pocket 6. Biochemical and Biophysical Research Communications 307 148–156. doi:10.1016/S0006-291X(03)01129-Xspa
dc.relation.referencesDay, Cheryl L, Nilufer P Seth, Michaela Lucas, Heiner Appel, Laurent Gauthier, Georg M Lauer, Gregory K Robbins, et al. 2003. “Ex Vivo Analysis of Human Memory CD4 T Cells Specific for Hepatitis C Virus Using MHC Class II Tetramers” 112 (6): 831–42. doi:10.1172/JCI200318509spa
dc.relation.referencesYu, Yang, Dongdong Jin, Shizong Hu, Yan Zhang, Xiaojing Zheng, Jianhua Zheng, Mingfeng Liao, et al. 2015. “A Novel Tuberculosis Antigen Identified from Human Tuberculosis Granulomas.” Molecular & Cellular Proteomics 14 (4): 1093–1103. doi:10.1074/mcp.M114.045237.spa
dc.relation.referencesYin, L., Maben, Z., Becerra, A., & Stern, L. J. (2015). Evaluating the role of HLA-DM in MHC II-peptide association reactions. Journal of Immunology (Baltimore, Md. : 1950), 195(2), 706–716. http://doi.org/10.4049/jimmunol.1403190spa
dc.relation.referencesHurwitz, Julia L. 2011. “Respiratory Syncytial Virus Vaccine Development.” Expert Review of Vaccines. doi:10.1586/erv.11.120.spa
dc.relation.referencesChanock, Robert M, Keith Jensen, and Robert H Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine1- 2- 89(4): 422–34.spa
dc.relation.referencesGraham, Barney S. 2016. “Vaccines against Respiratory Syncytial Virus: The Time Has Finally Come.” Vaccine 34 (30). Elsevier Ltd: 3535–41. doi:10.1016/j.vaccine.2016.04.083.spa
dc.relation.referencesHiggins, Deborah, Carrie Trujillo, and Cheryl Keech. 2016. “Advances in RSV Vaccine Research and Development - A Global Agenda.” Vaccine 34 (26). Elsevier Ltd: 2870–75. doi:10.1016/j.vaccine.2016.03.109.spa
dc.relation.referencesRudraraju, R., Jones, B. G., Sealy, R., Surman, S. L., & Hurwitz, J. L. (2013). Respiratory syncytial virus: current progress in vaccine development. Viruses, 5(2), 577–94. https://doi.org/10.3390/v5020577spa
dc.relation.referencesJ. Díez y V. Planelles.2011. Vacuna frente al virus respiratorio sincitial. An Pediatr Contin; 9(1):64-8. http://appswl.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=80000599&pident_usuario=0&pcontactid=&pident_revista=51&ty=130&accion=L&origen=apccontinuada&web=www.apcontinuada.com&lan=es&fichero=v9n1a499pdf001.pdf&anuncioPdf=ERROR_publi_pdf&fbclid=IwAR0c_jnEkHdXA1XLCl83ySN4-10ZkQuVYBNHDKfIaio2nmtrgL90TjlBjq8spa
dc.relation.referencesRodríguez Libia M, Giraldo Mabel C, García Natalia, Velásquez Laura, París Sara C, Álvarez Cristiam M et al . Frecuencias alélicas, genotípicas y haplotípicas HLA-A, HLA-B, HLA-DRB1 en donantes fallecidos, Medellín, Colombia. Biomédica [Internet]. 2007 Dec [cited 2018 Oct 27]; 27( 4 ): 537-547. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-41572007000400009&lng=enspa
dc.relation.referencesZhang, Lianming, Yiqing Chen, Hau San Wong, Shuigeng Zhou, Hiroshi Mamitsuka, and Shanfeng Zhu. 2012. “TepitopePan: Extending Tepitope for Peptide Binding Prediction Covering over 700 Hla-Dr Molecules.” PLoS ONE 7 (2). doi:10.1371/journal.pone.0030483spa
dc.relation.referencesSingh, Harpreet, and G. P.S. Raghava. 2002. “ProPred: Prediction of HLA-DR Binding Sites.” Bioinformatics 17 (12): 1236–37. doi:10.1093/bioinformatics/17.12.1236.spa
dc.relation.referencesNielsen, Morten, Ole Lund, Soren Buus, and Claus Lundegaard. 2010. “MHC Class II Epitope Predictive Algorithms.” Immunology. doi:10.1111/j.1365-2567.2010.03268.x.spa
dc.relation.referencesChaves, F. A., Lee, A. H., Nayak, J., Richards, K. A., & Sant, A. J. (2012). The utility and limitations of current web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection . Journal of Immunology (Baltimore, Md. : 1950), 188(9), 4235–4248. doi:10.4049/jimmunol.1103640.spa
dc.relation.referencesMarek Wieczorek, Esam T, Front Immunol. 2017; 8: 292. Published online 2017 Mar 17,Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355494/spa
dc.relation.referencesSecretaria distrital de salud.Curso basico de medicina transfusional.editorial maldonado SAspa
dc.relation.referencesDeborah A. Lipski, Rémi Dewispelaere,MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis J Neuroinflammation. 2017; 14: 136spa
dc.relation.referencesBrown, J H, T S Jardetzky, J C Gorga, L J Stern, R G Urban, J L Strominger, and D C Wiley. 1993. “Three-Dimensional Structure of the Human Class II Histocompatibility Antigen HLA-DR1.” Nature 364 (6432): 33–39. doi:10.1038/364033a0spa
dc.relation.referencesWilliam Sherwin, Lars, Bejder, Celine Frère, Michael Krützen, Janet Mann, Tracey Rogers. Fitness & major histocompatibility complex diversity of two bottlenose dolphin populations DOI: 10.13140/RG.2.1.1804.2480.spa
dc.relation.referencesPainter, Corrie A, and Lawrence J Stern. 2011. “Structural Insights Into HLA-DM Mediated MHC II Peptide Exchange.” Current Topics in Biochemical Research 13 (2): 39–55. doi:10.1016/j.biotechadv.2011.08.021.Secreted.spa
dc.relation.referencesBian, Hongjin, John F. Reidhaar-Olson, and Juergen Hammer. 2003. “The Use of Bioinformatics for Identifying Class II-Restricted T-Cell Epitopes.” Methods 29 (3). Academic Press Inc.: 299–309. doi:10.1016/S1046-2023(02)00352-3.spa
dc.relation.referencesMecanismos de procesamiento y presentación antigénica en autoinmunidad. Universidad Autónoma de Barcelona, Bellaterra Mayo 2017spa
dc.relation.referencesBraendstrup P, Mortensen BK, Justesen S, Østerby T, Rasmussen M, et al. (2014) Identification and HLA-Tetramer-Validation of Human CD4+ and CD8+ T Cell Responses against HCMV Proteins IE1 and IE2. PLoS ONE 9(4): doi:10.1371/journal.pone.0094892spa
dc.relation.referencesBlazekovic, F., Odukoya, D., Butler, S. N., Mauro, J. A., Ramsamooj, M., Puleo, E. Blanck, G. (2016). HLA-DR peptide occupancy can be regulated with a wide variety of small molecules. Human Vaccines and Immunotherapeutics, 12(3), 593–598. https://doi.org/10.1080/21645515.2015.1089370spa
dc.relation.referencesSteven G.E. Marsh, Peter Parham, Linda D. Barber. THE HLA. FactsBook Academic press.92101-4495. USA. Capítulo 7. Pag.41-73.spa
dc.relation.referencesRammensee, H G. 1995. “Chemistry of Peptides Associated with MHC Class I and Class II Molecules.” Curr Opin Immunol 7 (1): 85–96. doi:0952-7915(95)80033-6.spa
dc.relation.referencesMatsumura, M, D H Fremont, P a Peterson, and I a Wilson. 1992. “Emerging Principles for the Recognition of Peptide Antigens by MHC Class I Molecules.” Science 257 (1991): 927–34.spa
dc.relation.referencesScott Southwood, John Sidney, Akihiro Kondo, Marie-France del Guercio, Ettore Appella, Stephen Hoffman, Ralph T. Kubo, Robert W. Chesnut, Howard M Grey and Alessandro Sette. 1998, Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires J Immunol. J Immunol 1998; 160:3363-3373; http://www.jimmunol.org/content/160/7/3363spa
dc.relation.referencesHLA-DRB1 major histocompatibility complex, class II, DR beta Gene ID: 3123.spa
dc.relation.referencesDominguez Horta, María, y Noraylis Lorenzo Pérez, y Ariana Barbera Betancourt, y María Victoria Hernández Cuellar, y Ana María Torres Lima, y M. Nazabal, y H. Camacho, e Isabel María Hernández Cuellar, y Neisy Ortiz, y V. Morera, y Ramón Gabriel Padrón Palomares. 2006. "Caracterización de Moléculas HLA tipo II y evaluación de citocinas en pacientes cubanos con Artritis Reumatoide". Revista Cubana de Reumatología 8 (9-10): 43-51spa
dc.relation.referencesJúlia Kurkó Et al. 2013 Genetics of Rheumatoid Arthritis:A Comprehensive Review. Clin Rev Allergy Immunol; 45(2): 170–179. doi:10.1007/s12016-012-8346-7.spa
dc.relation.referencesAlbert J. C Zaja,Michael P. Manns,2010,Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis,GASTROENTEROLOGY ;139:58 –72,doi:10.1053/j.gastro.2010.04.053spa
dc.relation.referencesKareem Sassi ,Jose M. Nieto ,Sammy Saab 2015,– Trasplante de Hepatitis Autoinmune, páginas 174-188, Capítulo 15spa
dc.relation.referencesPos, W. et al. (2012) Crystal structure of the HLA-DM–HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell 151, 1557–1568spa
dc.relation.referencesYin, Liusong, and Lawrence J. Stern. 2013. “HLA-DM Focuses on Conformational Flexibility Around P1 Pocket to Catalyze Peptide Exchange.” Frontiers in Immunology 4. doi:10.3389/fimmu.2013.00336spa
dc.relation.referencesLiusong Yin, Zachary J. Maben, Aniuska Becerra and Lawrence J. Stern J Immunol July 15, 2015, 195 (2) 706-716; Evaluating the Role of HLA-DM in MHC Class II–Peptide Association Reactions DOI: https://doi.org/10.4049/jimmunol.1403190spa
dc.relation.referencesGilca, Rodica, Gaston De Serres, Mireille Tremblay, Marie-Louise Vachon, Eric Leblanc, Michel G Bergeron, Pierre Dery, and Guy Boivin. 2006. “Distribution and Clinical Impact of Human Respiratory Syncytial Virus Genotypes in Hospitalized Children over 2 Winter Seasons.” The Journal of Infectious Diseases 193: 54–58. doi:10.1086/498526.spa
dc.relation.referencesVandini, Silvia, Carlotta Biagi, and Marcello Lanari. 2017. “Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.” International Journal of Molecular Sciences. MDPI AG. doi:10.3390/ijms18081717.spa
dc.relation.referencesJohansson, Cecilia. 2016. “Respiratory Syncytial Virus Infection: An Innate Perspective.” F1000Research 5 (December): 2898. doi:10.12688/f1000research.9637.1.spa
dc.relation.referencesMelero, José A., Vicente Mas, and Jason S. McLellan. 2017. “Structural, Antigenic and Immunogenic Features of Respiratory Syncytial Virus Glycoproteins Relevant for Vaccine Development.” Vaccine 35 (3). Elsevier Ltd: 461–68. doi:10.1016/j.vaccine.2016.09.045.spa
dc.relation.referencesGriffiths C, Drews SJ, Marchant DJ. 2017. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev 30:277–319. https://doi.org/10.1128/CMR.00010-16spa
dc.relation.referencesEmma Rey-Jurado and Alexis M. Kalergis.2017. Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia—Implications for Vaccine Design.Int. J. Mol. Sci., 18, 556; doi:10.3390/ijms18030556spa
dc.relation.referencesNicolás M. S. Gálvez, Jorge A. Soto, Alexis M. Kalergis,2017, New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV. Int. J. Mol. Sci., 18, 1753; doi:10.3390/ijms18081753.spa
dc.relation.referencesAlexander Kotelkin, Igor M. Belyakov, Lijuan Yang, Jay A. Berzofsky, Peter L. Collins, and Alexander Bukreyev , 2006, The NS2 Protein of Human Respiratory Syncytial Virus Suppresses the Cytotoxic T-Cell Response as a Consequence of Suppressing the Type I Interferon Response. JOURNAL OF VIROLOGY,, p. 5958–5967 Vol. 80, doi:10.1128/JVI.00181-06.spa
dc.relation.referencesClaire P Straub, Wei-Har Lau, Faith M Preston, Madeleine J Headlam, Jeffery J Gorman, Peter L Collins and Kirsten M Spann,2011, Mutation of the elongin C binding domain of human respiratory syncytial virus non-structural protein 1 (NS1) results in degradation of NS1 and attenuation of the virus. Straub et al. Virology Journal, 8:252 https://doi.org/10.1186/1743-422X-8-252spa
dc.relation.referencesHastie M et al. 2012 The Human Respiratory Syncytial Virus Nonstructural Protein 1 Regulates Type I and Type II Interferon Pathways.Molecular & Cellular Proteomics 11: 10.1074/ mcp.M111.015909, 108 –127spa
dc.relation.referencesPeter L. Collins. Rachel Fearns. Barney S. Graham,2013, espinoza Curr Top Microbiol Immunol. 2013; 372: 3–38. Doi:10.1007/978-3-642-38919-1_1.spa
dc.relation.referencesCéspedes P et al. .2014,Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells. PNAS,DOI:10.1073/pnas.1400760111.spa
dc.relation.referencesRuchira Mitra, Pradyumna Baviskar, Rebecca R, 2012, Duncan-Decocq, Darshna Patel, and Antonius G. P. Oomens. The Human Respiratory Syncytial Virus Matrix Protein Is Required for Maturation of Viral Filaments. Journal of Virology p. 4432–4443. 2012.DOI:10.1128/JVI.06744-11spa
dc.relation.referencesGhildyal, Reena, Adeline Ho, and David A. Jans. 2006. “Central Role of the Respiratory Syncytial Virus Matrix Protein in Infection.” FEMS Microbiology Reviews. doi:10.1111/j.1574-6976.2006.00025.x.spa
dc.relation.referencesLiang, Bo, Sonja Surman, Emerito Amaro-Carambot, Barbora Kabatova, Natalie Mackow, Matthias Lingemann, Lijuan Yang, et al. 2015. “Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.”. Journal of Virology 89 (18): 9499–9510. doi:10.1128/JVI.01373-15.spa
dc.relation.referencesRossey, Iebe, Jason S. McLellan, Xavier Saelens, and Bert Schepens. 2017. “Clinical Potential of Prefusion RSV F-Specific Antibodies.” Trends in Microbiology. doi:10.1016/j.tim.2017.09.009.spa
dc.relation.referencesGagliardi T, B, Criado M, F, Proença-Módena J, L, Saranzo A, M, Iwamoto M, A, de Paula F, E, Cardoso R, S, Delcaro L, S, Silva M, L, Câmara A, A, Arruda E: Syncytia Induction by Clinical Isolates of Human Respiratory Syncytial Virus A. Intervirology 2017;60:56-60. doi: 10.1159/000480014spa
dc.relation.referencesCarter, Stephen D., Kyle C. Dent, Elizabeth Atkins, Toshana L. Foster, Mark Verow, Petra Gorny, Mark Harris, et al. 2010. “Direct Visualization of the Small Hydrophobic Protein of Human Respiratory Syncytial Virus Reveals the Structural Basis for Membrane Permeability.” FEBS Letters 584 (13): 2786–90. doi:10.1016/j.febslet.2010.05.006.spa
dc.relation.referencesFuentes, S., K. C. Tran, P. Luthra, M. N. Teng, and B. He. 2007. “Function of the Respiratory Syncytial Virus Small Hydrophobic Protein.” Journal of Virology 81 (15): 8361–66. doi:10.1128/JVI.02717-06.spa
dc.relation.referencesSchepens, Bert, Koen Sedeyn, Liesbeth Vande Ginste, Sarah De Baets, Michael Schotsaert, Kenny Roose, Lieselot Houspie, et al. 2014. “Protection and Mechanism of Action of a Novel Human Respiratory Syncytial Virus Vaccine Candidate Based on the Extracellular Domain of Small Hydrophobic Protein.” EMBO Mol Med 6: 1436–54. doi:10.15252/emmm.201404005.spa
dc.relation.referencesSchepens, Bert. 2015. “Small Hydrophobic Protein of Respiratory Syncytial Virus as a Novel Vaccine Antigen.” Immunotherapy 7: 203–6. doi:10.2217/imt.15.11.spa
dc.relation.referencesMelero, José A., Vicente Mas, and Jason S. McLellan. 2017. “Structural, Antigenic and Immunogenic Features of Respiratory Syncytial Virus Glycoproteins Relevant for Vaccine Development.” Vaccine 35 (3). Elsevier Ltd: 461–68. doi:10.1016/j.vaccine.2016.09.045.spa
dc.relation.referencesBoyoglu-Barnum S, Todd SO, Meng J, Barnum TR, Chirkova T, Haynes LM, Jadhao SJ, Tripp RA, Oomens AG, Moore ML, Anderson LJ. 2017. Mutating the CX3C motif in the G protein should make a live respiratory syncytial virus vaccine safer and more effective. J Virol 91:e02059-16. https:// doi.org/10.1128/JVI.02059-16.spa
dc.relation.referencesChirkova, Tatiana, Songbai Lin, Antonius G P Oomens, Kelsey A Gaston, Seyhan Boyoglu-Barnum, Jia Meng, Christopher C Stobart, et al. 2015. “CX3CR1 Is an Important Surface Molecule for Respiratory Syncytial Virus Infection in Human Airway Epithelial Cells.” The Journal of General Virology 96 (9). Microbiology Society: 2543–56. doi:10.1099/vir.0.000218.spa
dc.relation.referencesFix, J., Galloux, M., Blondot, M. L., & Eléouët, J. F. (2011). The insertion of fluorescent proteins in a variable region of respiratory syncytial virus L polymerase results in fluorescent and functional enzymes but with reduced activities. The open virology journal, 5, 103-8spa
dc.relation.referencesCastagné, Nathalie, Alexandra Barbier, Julie Bernard, Human Rezaei, Jean Claude Huet, Céline Henry, Bruno Da Costa, and Jean François Eléouët. 2004. “Biochemical Characterization of the Respiratory Syncytial Virus P-P and P-N Protein Complexes and Localization of the P Protein Oligomerization Domain.” Journal of General Virology 85 (6): 1643–53. doi:10.1099/vir.0.79830-0.spa
dc.relation.referencesEspinoza J, Bueno S, Riedel C, Kalergis A. 2014 Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine designImmunology, 143, 1–12. doi:10.1111/imm.12313spa
dc.relation.referencesRey-Jurado, E., & Kalergis, A. M. (2017). Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design. International journal of molecular sciences, 18(3), 556. doi:10.3390/ijms18030556spa
dc.relation.referencesMylene Corzo-López y Odalys Valdés-Ramírez.* El virus sincitial respiratorio humano: una panorámica, Revista CENIC Ciencias Biológicas, Vol. 44, No. 2, mayo-agosto, 2013.http://www.redalyc.org/pdf/1812/181227534005.pdfspa
dc.relation.referencesChartrand, C., Tremblay, N., Renaud, C., & Papenburg, J. (2015). Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis. Journal of clinical microbiology, 53(12), 3738-49.spa
dc.relation.referencesPilie, P., W. A. Werbel, J. Riddell, X. Shu, D. Schaubel, and K. S. Gregg. 2015. “Adult Patients with Respiratory Syncytial Virus Infection: Impact of Solid Organ and Hematopoietic Stem Cell Transplantation on Outcomes.” Transplant Infectious Disease 17 (4). Blackwell Publishing Inc.: 551–57. doi:10.1111/tid.12409.spa
dc.relation.referencesPaes, Bosco A., Ian Mitchell, Anna Banerji, Krista L. Lanctôt, and Joanne M. Langley. 2011. “A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice.” Canadian Respiratory Journal. Hindawi Limited. doi:10.1155/2011/493056.spa
dc.relation.referencesBont, Louis, Paul A. Checchia, Brigitte Fauroux, Josep Figueras-Aloy, Paolo Manzoni, Bosco Paes, Eric A.F. and Xavier Carbonell-Estrany. 2016. “Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries.” Infectious Diseases and Therapy. Springer Healthcare. doi:10.1007/s40121-016-0123-0spa
dc.relation.referencesRobbie, G. J., Criste, R., Dall'acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013). A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrobial agents and chemotherapy, 57(12), 6147-53.spa
dc.relation.referencesGraham BS,(2016) , Vaccines against respiratory syncytial virus: The time has finally come. Vaccine , http://dx.doi.org/10.1016/j.vaccine.2016.04.083spa
dc.relation.referencesJ.A. Bastarache, T. Koyama, N.E Wickersham, and L.B. Ware, 2014 ;. Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples.J Immunol Methods, doi:10.1016/j.jim.2014.04.006.spa
dc.relation.referencesRojas-Caraballo, J., López-Abán, J., Pérez Del Villar, L., Vizcaíno, C., Vicente, B., Fernández-Soto, P., Muro, A. (2014). In vitro and in vivo studies for assessing the immune response and protection-inducing ability conferred by Fasciola hepatica-derived synthetic peptides containing B- and T-cell epitopes. PLoS ONE, 9(8). https://doi.org/10.1371/journal.pone.0105323spa
dc.relation.referencesCreech AL, Ting YS,2018,The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction.Proteomics. doi: 10.1002/pmic.201700259.spa
dc.relation.referencesL.E VARGAS,2011, Influencia de HLA-DM en la estabilidad del complejo formado entre la molécula HLA-DR4 y un péptido de la proteína CS de P. falciparum. Universidad Nacional Facultad de Medicina, http://bdigital.unal.edu.co/8745/1/597342.2011.pdfspa
dc.relation.referencesYin, Liusong, Peter Trenh, Abigail Guce, Marek Wieczorek, Sascha Lange, Jana Sticht, Wei Jiang, et al. 2014. “Susceptibility to HLA-DM Protein Is Determined by a Dynamic Conformation of Major Histocompatibility Complex Class II Molecule Bound with Peptide.” Journal of Biological Chemistry 289 (34). American Society for Biochemistry and Molecular Biology Inc.: 23449–64. doi:10.1074/jbc.M114.585539spa
dc.relation.referencesYin, L., J. M. Calvo-Calle, O. Dominguez-Amorocho, and L. J. Stern. 2012. “HLA-DM Constrains Epitope Selection in the Human CD4 T Cell Response to Vaccinia Virus by Favoring the Presentation of Peptides with Longer HLA-DM-Mediated Half-Lives.” The Journal of Immunology 189 (8): 3983–94. doi:10.4049/jimmunol.1200626.spa
dc.relation.referencesHall, Frances C., Joshua D. Rabinowitz, Robert Busch, Kevin C. Visconti, Michael Belmares, Namrata S. Patil, Andrew P. Cope, et al. 2002. “Relationship between Kinetic Stability and Immunogenicity of HLA- DR4/Peptide Complexes.” European Journal of Immunology 32 (3): 662–70. doi:10.1002/1521-4141(200203)32:3<662::AID-IMMU662>3.0.CO;2-5.spa
dc.relation.referencesLin, Hong Huang, Guang Lan Zhang, Songsak Tongchusak, Ellis L. Reinherz, and Vladimir Brusic. 2008. “Evaluation of MHC-II Peptide Binding Prediction Servers: Applications for Vaccine Research.” In BMC Bioinformatics. Vol. 9. doi:10.1186/1471-2105-9-S1-S22spa
dc.relation.referencesAchal Pashine, Robert Busch, 2003, Interaction of HLA-DR with an Acidic Face of HLA-DM Disrupts Sequence-Dependent Interactions with Peptides. Immunity, Vol. 19, 183–192,DOI:https://doi.org/10.1016/S1074-7613(03)00200-0.spa
dc.relation.referencesViviana Marin-Esteban, Kirsten Falk,Chemical ,2004,Analogues of HLA-DM Can Induce a Peptide-receptive State in HLA-DR Molecules. JBC Papers in Press, DOI 10.1074/jbc.M407598200.spa
dc.relation.referencesAlvarado A, Tenorio G.V R, Aguilar S,A, Sandoval T,AH.2006.Promesas y limitaciones de las vacunas antigénicas. Revista Mexicana de ciencias Farmacéuticas. [Internet]:37(2):26-37. http://www.redalyc.org/pdf/579/57937205.pdfspa
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccessspa
dc.rights.creativecommonsAtribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)spa
dc.subject.lembEl Virus Sincitial Respiratorio
dc.subject.lembPatologías Neuromusculares
dc.subject.lembBronquiolitis
dc.subject.lembParamyxoviridae
dc.subject.proposalPresentación de antígenosspa
dc.subject.proposalSelección de Epítopesspa
dc.subject.proposalComplejo MHC II/Péptidospa
dc.subject.proposalSusceptibilidad HLA-DMspa
dc.subject.proposalAlgoritmos de unión a moléculas MHC clase IIspa
dc.subject.proposalMoléculas HLA-DR1 y DR4spa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.redcolhttps://purl.org/redcol/resource_type/TPspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.rights.coarhttp://purl.org/coar/access_right/c_14cbspa


Ficheros en el ítem

Thumbnail
Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Universidad Colegio Mayor de Cundinamarca, 2019
Excepto si se señala otra cosa, la licencia del ítem se describe como Universidad Colegio Mayor de Cundinamarca, 2019